EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY-NC 4.0

Evaluation of a Novel Peptide‐Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection

Alicia Majeau iD, Julio Vladimir Cruz-Chan iD, Etienne Waleckx iD, Eric Dumonteil iD, Claudia Herrera iD

Clinical and Translational Science · 2026-08 · 19 (8)

DOI: 10.1111/cts.70676 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Clinical and Translational Science, online erschienen am 24.07.2026. Verfasst von Alicia Majeau und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Medicine and Infectious Disease, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, New…. Hauptthemen laut MEDLINE: Chagas Disease, Trypanosoma cruzi, Serologic Tests, Antigens, Protozoan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease is a neglected tropical disease endemic in most of the Americas, caused by Trypanosoma cruzi . New serological tests with improved performance are urgently needed for accurate diagnosis of T. cruzi infections. We evaluated here the performance of a novel peptide ELISA based on highly conserved parasite antigens, using a large panel of well characterized samples ( N = 308) from Mexico, where serological discordance is particularly high. Comparison of peptide ELISA with various serological and molecular assays indicated that it outperformed an FDA‐approved commercial ELISA in terms of sensitivity (47.5% vs. 28.3% compared with PCR), while a high specificity was maintained (80.3%–91.2% compared with PCR or serology plus PCR). Improved sensitivity was due to the reactivity of samples previously characterized as serodiscordants. Nonetheless, test performance remains limited for stand‐alone use but may complement current tests. Further optimizing antigen composition to include additional highly conserved antigens may allow reaching optimum levels of test performance to simplify serological diagnosis of T. cruzi infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseTrypanosoma cruziSerologic TestsAntigens, ProtozoanPeptidesEnzyme-Linked Immunosorbent AssayHumansSensitivity and SpecificityMexicoAntibodies, ProtozoanPolymerase Chain Reaction

Substanzen

Antigens, ProtozoanPeptidesAntibodies, Protozoan

Autor:innen und Institutionen

  • Department of Tropical Medicine and Infectious Disease, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, USA.
  • Laboratorio de Parasitología, Centro de Investigaciones Regionales "Dr Hideyo Noguchi", Universidad Autónoma de Yucatán, Mérida, Yucatán, México.
  • INTERTRYP, Université de Montpellier, Cirad, IRD, Montpellier, France.

ORCID-Profile: Alicia Majeau, Julio Vladimir Cruz-Chan, Etienne Waleckx, Eric Dumonteil, Claudia Herrera

Zitieren

APA

Majeau, A., Cruz-Chan, J. V., Waleckx, E., Dumonteil, E., & Herrera, C. (2026). Evaluation of a Novel Peptide‐Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70676

Vancouver

Majeau A, Cruz-Chan JV, Waleckx E, Dumonteil E, Herrera C. Evaluation of a Novel Peptide‐Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70676

BibTeX
@article{Majeau2026,
  author = {Majeau, Alicia and Cruz-Chan, Julio Vladimir and Waleckx, Etienne and Dumonteil, Eric and Herrera, Claudia},
  title = {Evaluation of a Novel Peptide‐Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1111/cts.70676}
}
Kostenlos starten →